SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.16-3.2%Dec 1 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (14200)7/23/2000 3:07:06 PM
From: LarryS  Read Replies (5) of 17367
 
In the race between Biogen and DNA/Xoma
to be first to market an anti-psoriasis
product, supposedly Biogen is in a slight
lead. But DNA has far more resources and
could set up more trial centers and catch
up with Biogen...or use their advantage in
money and personnel to get the test results/data done quicker than Biogen
to present to the FDA. I would bet
that DNA/Xoma will catch up and will present their case to the FDA at about the same time as Biogen. Ours is safer...it will be interesting to see what the FDA decides.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News